Paper17564707
Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Cashen AF and 4 others. Cancer Chemother Pharmacol, 2008. Cited by 80 papers, by iCite.
Cite this record
ConductScience Library. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Papers, record 17564707. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17564707
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antimetabolites, Antineoplastic | Major topic |
| Azacitidine | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Myelodysplastic Syndromes | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Area Under Curve | |
| Bone Marrow | |
| Chromatography, High Pressure Liquid | |
| Decitabine | |
| Drug Administration Schedule | |
| Female | |
| Half-Life | |
| Humans | |
| Infusions, Intravenous | |
| Male | |
| Mass Spectrometry | |
| Middle Aged | |
| Sepsis | |
| Tissue Distribution |
Source PubMed
Cited by54
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 80 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41987339 | DNMT3A in cancer: from epigenetic writer to oncogenic driver. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/41987339 | PubMed |
| 41679964 | DAXX promotes SUMOylation of chromatin-trapped DNMT1. | J Biochem | 2026 | https://conductscience.org/library/papers/41679964 | PubMed |
| 41610325 | Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML. | Blood Adv | 2026 | https://conductscience.org/library/papers/41610325 | PubMed |
| 41254518 | Decitabine-mediated DNA methylation dynamics at pericentromeric satellite 2 repeats. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41254518 | PubMed |
| 39472491 | A multiomics approach reveals RNA dynamics promote cellular sensitivity to DNA hypomethylation. | Sci Rep | 2024 | https://conductscience.org/library/papers/39472491 | PubMed |
| 39169233 | Tumor editing suppresses innate and adaptive antitumor immunity and is reversed by inhibiting DNA methylation. | Nat Immunol | 2024 | https://conductscience.org/library/papers/39169233 | PubMed |
| 39006906 | Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review). | Mol Clin Oncol | 2024 | https://conductscience.org/library/papers/39006906 | PubMed |
| 38760575 | Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS. | EMBO J | 2024 | https://conductscience.org/library/papers/38760575 | PubMed |
| 38509812 | Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review. | J Oncol Pharm Pract | 2024 | https://conductscience.org/library/papers/38509812 | PubMed |
| 36536485 | DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation. | Clin Transl Med | 2022 | https://conductscience.org/library/papers/36536485 | PubMed |
| 35429619 | Recurrent transcriptional responses in AML and MDS patients treated with decitabine. | Exp Hematol | 2022 | https://conductscience.org/library/papers/35429619 | PubMed |
| 34257059 | Urinary retention after use of decitabine in acute myeloid leukemia: case report. | Hematol Transfus Cell Ther | 2023 | https://conductscience.org/library/papers/34257059 | PubMed |
| 34079760 | Decitabine Sensitizes the Radioresistant Lung Adenocarcinoma to Pemetrexed Through Upregulation of Folate Receptor Alpha. | Front Oncol | 2021 | https://conductscience.org/library/papers/34079760 | PubMed |
| 33958699 | Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. | Leukemia | 2021 | https://conductscience.org/library/papers/33958699 | PubMed |
| 33437371 | Reactivation of oncogenes involved in G1/S transcription and apoptosis pathways by low dose decitabine promotes HT29 human colon cancer cell growth in vitro. | Am J Transl Res | 2020 | https://conductscience.org/library/papers/33437371 | PubMed |
| 31375673 | Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. | Nat Commun | 2019 | https://conductscience.org/library/papers/31375673 | PubMed |
| 30962963 | Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. | ESMO Open | 2019 | https://conductscience.org/library/papers/30962963 | PubMed |
| 30579366 | Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies. | Diagn Pathol | 2018 | https://conductscience.org/library/papers/30579366 | PubMed |
| 30214687 | Vitamin C promotes decitabine or azacytidine induced DNA hydroxymethylation and subsequent reactivation of the epigenetically silenced tumour suppressor CDKN1A in colon cancer cells. | Oncotarget | 2018 | https://conductscience.org/library/papers/30214687 | PubMed |
| 29708513 | DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. | J Clin Invest | 2018 | https://conductscience.org/library/papers/29708513 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17564707
GET https://conductscience.org/api/papers/v1/17564707/cited_by?page=2